GeneThera, Inc. to Complete Additional Audit of Financials

WHEAT RIDGE, CO--(Marketwire - January 15, 2009) - GeneThera, Inc. (PINKSHEETS: GTHR) announced today its intention to maintain its status as Sarbanes-Oxley compliant. The company's Auditor, W. T. Uniack & Co. CPAs, should have the audit completed in February.

Although GeneThera is already a fully reporting company, it has elected to re-audit all of its prior financial statements due to the revocation of its previous auditors' PCAOB registration. This re-audit is also a condition of any future buyout or merger agreement.

GeneThera has maintained all financial reporting as required by Sarbanes-Oxley in order to have its trading status upgraded to NASDAQ requirements.

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Al Goldsmith of The Goldsmith Group LLC at 303-463-6371 Ext. 206.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.